Treventis Partners its Preclinical Program in Alzheimer’s Disease with Takeda

Previous PostSIRPant Immunotherapeutics Announces FDA Clearance of IND Application for SIRPant-M™ Autologous SIRPαlow Activated Macrophage Immunotherapy